Profound Medical

Profound Medical

Canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. Learn more

Launch date
Market cap
CAD260m
Enterprise valuation
CAD222m (Public information from Sep 2024)
Mississauga Ontario (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
CAD2020202120222023202420252026
Revenues10.0m9.4m9.1m9.8m15.4m38.9m65.2m
% growth135 %(6 %)(3 %)8 %57 %152 %68 %
EBITDA(22.7m)(38.7m)(34.7m)(35.4m)(36.8m)(18.3m)1.7m
% EBITDA margin(228 %)(413 %)(381 %)(361 %)(239 %)(47 %)3 %
Profit(29.5m)(41.9m)(39.1m)(39.0m)(39.2m)(29.8m)(22.6m)
% profit margin(296 %)(447 %)(429 %)(397 %)(254 %)(77 %)(35 %)
EV / revenue51.6x31.6x33.2x24.7x19.6x7.8x4.6x
EV / EBITDA-22.7x-7.7x-8.7x-6.8x-8.2x-16.6x181.6x
R&D budget13.5m20.8m20.0m19.6m---
R&D % of revenue136 %222 %220 %200 %---
  • Edit

Recent News about Profound Medical

Edit
More about Profound Medicalinfo icon
Edit

Profound Medical is a pioneering healthcare company specializing in customizable, incision-free ablation therapies. The company leverages advanced technologies such as real-time Magnetic Resonance (MR) Imaging, thermal ultrasound, and closed-loop temperature feedback to offer innovative treatment solutions. Profound Medical primarily serves healthcare providers and patients, focusing on conditions like prostate cancer. Operating in the medical technology market, the company employs a business model centered around the development, manufacturing, and sale of its proprietary therapy platforms. Revenue is generated through the sale of medical devices and related services, including training and support for healthcare professionals.

Keywords: ablation therapies, MR imaging, thermal ultrasound, prostate cancer, healthcare, medical technology, non-invasive, customizable treatments, closed-loop feedback, medical devices.